Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Oyster Point Pharma, Inc.
Report date January 03, 2023 · Filed January 05, 2023
Jointly reported with InvOpps GP IV, L.L.C., InvOpps IV, L.P., LAINOVIC SACHA
Section 16 reporting ended · disclosed 2023-01-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectSee Footnotes | 0 |
Reported balance
After 2023-01-03 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-01-03 · Other · Disposed 917,768 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement") by and among Viatris Inc. ("Viatris") and Viatris's wholly owned subsidiary, Iris Purchaser Inc. dated as of November 7, 2022, these shares of common stock, par value $0.001 per share were tendered prior to the Offer Expiration Time (as defined in the Merger Agreement) and disposed of at the Effective Time (as defined in the Merger Agreement) in exchange for the right to receive (a) a cash payment of $11.00 per share (the "Cash Amount") and (b) one non-transferable contractual contingent value right representing the right to receive any applicable milestone payment if specified milestones are achieved pursuant to a Contingent Value Rights Agreement, dated January 3, 2023, by and between Viatris and American Stock Transfer & Trust Company, LLC as Rights Agent. F2: Reflects securities directly held by InvOpps IV US, L.P. ("Invus IV US"). F4: InvOpps GP IV, L.L.C. ("InvOpps GP") is the sole general partner of each of Invus IV and Invus IV US. Sacha Lainovic is the managing member of InvOpps GP. F5: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | IndirectSee Footnotes | 0 |
Reported balance
After 2023-01-03 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2023-01-03 · Other · Disposed 1,850,818 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement") by and among Viatris Inc. ("Viatris") and Viatris's wholly owned subsidiary, Iris Purchaser Inc. dated as of November 7, 2022, these shares of common stock, par value $0.001 per share were tendered prior to the Offer Expiration Time (as defined in the Merger Agreement) and disposed of at the Effective Time (as defined in the Merger Agreement) in exchange for the right to receive (a) a cash payment of $11.00 per share (the "Cash Amount") and (b) one non-transferable contractual contingent value right representing the right to receive any applicable milestone payment if specified milestones are achieved pursuant to a Contingent Value Rights Agreement, dated January 3, 2023, by and between Viatris and American Stock Transfer & Trust Company, LLC as Rights Agent. F3: Reflects securities directly held by InvOpps IV, L.P. ("Invus IV"). F4: InvOpps GP IV, L.L.C. ("InvOpps GP") is the sole general partner of each of Invus IV and Invus IV US. Sacha Lainovic is the managing member of InvOpps GP. F5: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement") by and among Viatris Inc. ("Viatris") and Viatris's wholly owned subsidiary, Iris Purchaser Inc. dated as of November 7, 2022, these shares of common stock, par value $0.001 per share were tendered prior to the Offer Expiration Time (as defined in the Merger Agreement) and disposed of at the Effective Time (as defined in the Merger Agreement) in exchange for the right to receive (a) a cash payment of $11.00 per share (the "Cash Amount") and (b) one non-transferable contractual contingent value right representing the right to receive any applicable milestone payment if specified milestones are achieved pursuant to a Contingent Value Rights Agreement, dated January 3, 2023, by and between Viatris and American Stock Transfer & Trust Company, LLC as Rights Agent.
F2: Reflects securities directly held by InvOpps IV US, L.P. ("Invus IV US").
F3: Reflects securities directly held by InvOpps IV, L.P. ("Invus IV").
F4: InvOpps GP IV, L.L.C. ("InvOpps GP") is the sole general partner of each of Invus IV and Invus IV US. Sacha Lainovic is the managing member of InvOpps GP.
F5: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2023 Filed Jan 5, 2023 16:30 UTC | Oyster Point Pharma, Inc. OYST · Entity 15903 | OtherCommon Stock, par value $0.001 per share | 1,850,818 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-000999 · doc4.xml · nonDerivative · entry 2 InvOpps GP IV, L.L.C. · CIK 0001792570 · Director · 10% owner InvOpps IV, L.P. · CIK 0001792575 · Director · 10% owner InvOpps IV US, L.P. · CIK 0001745076 · Director · 10% owner LAINOVIC SACHA · CIK 0001053891 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 F1 · shares: Pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement") by and among Viatris Inc. ("Viatris") and Viatris's wholly owned subsidiary, Iris Purchaser Inc. dated as of November 7, 2022, these shares of common stock, par value $0.001 per share were tendered prior to the Offer Expiration Time (as defined in the Merger Agreement) and disposed of at the Effective Time (as defined in the Merger Agreement) in exchange for the right to receive (a) a cash payment of $11.00 per share (the "Cash Amount") and (b) one non-transferable contractual contingent value right representing the right to receive any applicable milestone payment if specified milestones are achieved pursuant to a Contingent Value Rights Agreement, dated January 3, 2023, by and between Viatris and American Stock Transfer & Trust Company, LLC as Rights Agent. F1 · price: Pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement") by and among Viatris Inc. ("Viatris") and Viatris's wholly owned subsidiary, Iris Purchaser Inc. dated as of November 7, 2022, these shares of common stock, par value $0.001 per share were tendered prior to the Offer Expiration Time (as defined in the Merger Agreement) and disposed of at the Effective Time (as defined in the Merger Agreement) in exchange for the right to receive (a) a cash payment of $11.00 per share (the "Cash Amount") and (b) one non-transferable contractual contingent value right representing the right to receive any applicable milestone payment if specified milestones are achieved pursuant to a Contingent Value Rights Agreement, dated January 3, 2023, by and between Viatris and American Stock Transfer & Trust Company, LLC as Rights Agent. F3 · ownership.nature: Reflects securities directly held by InvOpps IV, L.P. ("Invus IV"). F4 · ownership.nature: InvOpps GP IV, L.L.C. ("InvOpps GP") is the sole general partner of each of Invus IV and Invus IV US. Sacha Lainovic is the managing member of InvOpps GP. F5 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 16:30 UTC | Oyster Point Pharma, Inc. OYST · Entity 15903 | OtherCommon Stock, par value $0.001 per share | 917,768 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-000999 · doc4.xml · nonDerivative · entry 1 InvOpps GP IV, L.L.C. · CIK 0001792570 · Director · 10% owner InvOpps IV, L.P. · CIK 0001792575 · Director · 10% owner InvOpps IV US, L.P. · CIK 0001745076 · Director · 10% owner LAINOVIC SACHA · CIK 0001053891 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 F1 · shares: Pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement") by and among Viatris Inc. ("Viatris") and Viatris's wholly owned subsidiary, Iris Purchaser Inc. dated as of November 7, 2022, these shares of common stock, par value $0.001 per share were tendered prior to the Offer Expiration Time (as defined in the Merger Agreement) and disposed of at the Effective Time (as defined in the Merger Agreement) in exchange for the right to receive (a) a cash payment of $11.00 per share (the "Cash Amount") and (b) one non-transferable contractual contingent value right representing the right to receive any applicable milestone payment if specified milestones are achieved pursuant to a Contingent Value Rights Agreement, dated January 3, 2023, by and between Viatris and American Stock Transfer & Trust Company, LLC as Rights Agent. F1 · price: Pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement") by and among Viatris Inc. ("Viatris") and Viatris's wholly owned subsidiary, Iris Purchaser Inc. dated as of November 7, 2022, these shares of common stock, par value $0.001 per share were tendered prior to the Offer Expiration Time (as defined in the Merger Agreement) and disposed of at the Effective Time (as defined in the Merger Agreement) in exchange for the right to receive (a) a cash payment of $11.00 per share (the "Cash Amount") and (b) one non-transferable contractual contingent value right representing the right to receive any applicable milestone payment if specified milestones are achieved pursuant to a Contingent Value Rights Agreement, dated January 3, 2023, by and between Viatris and American Stock Transfer & Trust Company, LLC as Rights Agent. F2 · ownership.nature: Reflects securities directly held by InvOpps IV US, L.P. ("Invus IV US"). F4 · ownership.nature: InvOpps GP IV, L.L.C. ("InvOpps GP") is the sole general partner of each of Invus IV and Invus IV US. Sacha Lainovic is the managing member of InvOpps GP. F5 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 19, 2020 Filed May 21, 2020 17:00 UTC | Oyster Point Pharma, Inc. OYST · Entity 15903 | PurchaseCommon Stock, par value $0.001 per share | 119,393 | $28.00 | $3,343,004.00 |
DisclosureSEC source: 0000899243-20-013881 · doc4.xml · nonDerivative · entry 2 InvOpps GP IV, L.L.C. · CIK 0001792570 · Director · 10% owner InvOpps IV, L.P. · CIK 0001792575 · Director · 10% owner InvOpps IV US, L.P. · CIK 0001745076 · Director · 10% owner LAINOVIC SACHA · CIK 0001053891 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,850,818 F2 · ownership.nature: Reflects securities directly held by InvOpps IV, L.P. ("Invus IV"). F3 · ownership.nature: InvOpps GP IV, L.L.C. ("InvOpps GP") is the sole general partner of each of Invus IV and Invus IV US. Sacha Lainovic is the managing member of InvOpps GP. F4 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 19, 2020 Filed May 21, 2020 17:00 UTC | Oyster Point Pharma, Inc. OYST · Entity 15903 | PurchaseCommon Stock, par value $0.001 per share | 59,178 | $28.00 | $1,656,984.00 |
DisclosureSEC source: 0000899243-20-013881 · doc4.xml · nonDerivative · entry 1 InvOpps GP IV, L.L.C. · CIK 0001792570 · Director · 10% owner InvOpps IV, L.P. · CIK 0001792575 · Director · 10% owner InvOpps IV US, L.P. · CIK 0001745076 · Director · 10% owner LAINOVIC SACHA · CIK 0001053891 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 917,768 F1 · ownership.nature: Reflects securities directly held by InvOpps IV US, L.P. ("Invus IV US"). F3 · ownership.nature: InvOpps GP IV, L.L.C. ("InvOpps GP") is the sole general partner of each of Invus IV and Invus IV US. Sacha Lainovic is the managing member of InvOpps GP. F4 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 16:30 UTC | Oyster Point Pharma, Inc. OYST · Entity 15903 | ConversionSeries B Convertible Preferred Stock · Derivative | 1,230,050 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-026771 · doc4.xml · derivative · entry 6 InvOpps GP IV, L.L.C. · CIK 0001792570 · Director · 10% owner InvOpps IV, L.P. · CIK 0001792575 · Director · 10% owner InvOpps IV US, L.P. · CIK 0001745076 · Director · 10% owner LAINOVIC SACHA · CIK 0001053891 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 per share · 1,230,050 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock (the "Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series B Convertible Preferred Stock had no expiration date. F1 · price: These shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock (the "Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series B Convertible Preferred Stock had no expiration date. F1 · derivative.exercise_date: These shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock (the "Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series B Convertible Preferred Stock had no expiration date. F1 · derivative.expiration_date: These shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock (the "Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series B Convertible Preferred Stock had no expiration date. F3 · ownership.nature: Reflects securities directly held by InvOpps IV, L.P. ("Invus IV"). F4 · ownership.nature: InvOpps GP IV, L.L.C. ("InvOpps GP") is the sole general partner of each of Invus IV and Invus IV US. Sacha Lainovic is the managing member of InvOpps GP. F5 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 16:30 UTC | Oyster Point Pharma, Inc. OYST · Entity 15903 | ConversionSeries B Convertible Preferred Stock · Derivative | 609,965 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-026771 · doc4.xml · derivative · entry 5 InvOpps GP IV, L.L.C. · CIK 0001792570 · Director · 10% owner InvOpps IV, L.P. · CIK 0001792575 · Director · 10% owner InvOpps IV US, L.P. · CIK 0001745076 · Director · 10% owner LAINOVIC SACHA · CIK 0001053891 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 per share · 609,965 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock (the "Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series B Convertible Preferred Stock had no expiration date. F1 · price: These shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock (the "Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series B Convertible Preferred Stock had no expiration date. F1 · derivative.exercise_date: These shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock (the "Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series B Convertible Preferred Stock had no expiration date. F1 · derivative.expiration_date: These shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock (the "Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series B Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Reflects securities directly held by InvOpps IV US, L.P. ("Invus IV US"). F4 · ownership.nature: InvOpps GP IV, L.L.C. ("InvOpps GP") is the sole general partner of each of Invus IV and Invus IV US. Sacha Lainovic is the managing member of InvOpps GP. F5 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 16:30 UTC | Oyster Point Pharma, Inc. OYST · Entity 15903 | PurchaseCommon Stock, par value $0.001 per share | 501,375 | $16.00 | $8,022,000.00 |
DisclosureSEC source: 0000899243-19-026771 · doc4.xml · nonDerivative · entry 4 InvOpps GP IV, L.L.C. · CIK 0001792570 · Director · 10% owner InvOpps IV, L.P. · CIK 0001792575 · Director · 10% owner InvOpps IV US, L.P. · CIK 0001745076 · Director · 10% owner LAINOVIC SACHA · CIK 0001053891 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,731,425 F3 · ownership.nature: Reflects securities directly held by InvOpps IV, L.P. ("Invus IV"). F4 · ownership.nature: InvOpps GP IV, L.L.C. ("InvOpps GP") is the sole general partner of each of Invus IV and Invus IV US. Sacha Lainovic is the managing member of InvOpps GP. F5 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 16:30 UTC | Oyster Point Pharma, Inc. OYST · Entity 15903 | PurchaseCommon Stock, par value $0.001 per share | 248,625 | $16.00 | $3,978,000.00 |
DisclosureSEC source: 0000899243-19-026771 · doc4.xml · nonDerivative · entry 3 InvOpps GP IV, L.L.C. · CIK 0001792570 · Director · 10% owner InvOpps IV, L.P. · CIK 0001792575 · Director · 10% owner InvOpps IV US, L.P. · CIK 0001745076 · Director · 10% owner LAINOVIC SACHA · CIK 0001053891 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 858,590 F2 · ownership.nature: Reflects securities directly held by InvOpps IV US, L.P. ("Invus IV US"). F4 · ownership.nature: InvOpps GP IV, L.L.C. ("InvOpps GP") is the sole general partner of each of Invus IV and Invus IV US. Sacha Lainovic is the managing member of InvOpps GP. F5 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 16:30 UTC | Oyster Point Pharma, Inc. OYST · Entity 15903 | ConversionCommon Stock, par value $0.001 per share | 1,230,050 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-026771 · doc4.xml · nonDerivative · entry 2 InvOpps GP IV, L.L.C. · CIK 0001792570 · Director · 10% owner InvOpps IV, L.P. · CIK 0001792575 · Director · 10% owner InvOpps IV US, L.P. · CIK 0001745076 · Director · 10% owner LAINOVIC SACHA · CIK 0001053891 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 1,230,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock (the "Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series B Convertible Preferred Stock had no expiration date. F3 · ownership.nature: Reflects securities directly held by InvOpps IV, L.P. ("Invus IV"). F4 · ownership.nature: InvOpps GP IV, L.L.C. ("InvOpps GP") is the sole general partner of each of Invus IV and Invus IV US. Sacha Lainovic is the managing member of InvOpps GP. F5 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 16:30 UTC | Oyster Point Pharma, Inc. OYST · Entity 15903 | ConversionCommon Stock, par value $0.001 per share | 609,965 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-026771 · doc4.xml · nonDerivative · entry 1 InvOpps GP IV, L.L.C. · CIK 0001792570 · Director · 10% owner InvOpps IV, L.P. · CIK 0001792575 · Director · 10% owner InvOpps IV US, L.P. · CIK 0001745076 · Director · 10% owner LAINOVIC SACHA · CIK 0001053891 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 609,965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock (the "Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Series B Convertible Preferred Stock had no expiration date. F2 · ownership.nature: Reflects securities directly held by InvOpps IV US, L.P. ("Invus IV US"). F4 · ownership.nature: InvOpps GP IV, L.L.C. ("InvOpps GP") is the sole general partner of each of Invus IV and Invus IV US. Sacha Lainovic is the managing member of InvOpps GP. F5 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.